Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC

作者
Xiaoting Gu,Jiaxiao Geng,Hongfu Sun,Qiang Cao,Yan Yi,Baosheng Li
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:15: 1707876-1707876
标识
DOI:10.3389/fonc.2025.1707876
摘要

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. We evaluated the value and safety of third-generation EGFR-TKIs combined with thoracic radiotherapy (TRT) in patients with oligo-organ metastatic, along with the optimal TRT timing and dose. Methods: We retrospectively enrolled patients with EGFR-mutated oligo-organ metastatic NSCLC who received first-line third-generation EGFR-TKIs from 2018 to 2023. Patients were divided into TKI-alone and TKI+TRT groups according to whether TRT was added. Propensity score matching (PSM) was implemented to decrease bias. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and safety. Results: A total of 236 patients were included, the median follow-up was 28.4 months. After PSM, baseline characteristics were balanced between the TKI+TRT (n=69) and TKI-alone (n=108) groups. Compared with the TKI-alone group, the TKI+TRT group presented significantly better PFS (28.6 vs. 19.8 months, hazard ratio [HR]=0.48, P = 0.00024) and OS (42.2 vs. 35.1 months, HR = 0.54, P = 0.039). In patients who received TRT, the tumor shrinkage group demonstrated significantly improved PFS (HR = 0.36, P = 0.0035) and OS (HR = 0.13, P = 0.0012) compared to the tumor enlargement/Stabilization group. The high-dose group showed superior PFS (HR = 0.43, P = 0.011) and OS (HR = 0.36, P = 0.023) compared to the low-dose group. Only 5.8% of patients in the TKI+TRT group developed grade ≥3 pneumonitis. Conclusion: Incorporating TRT provided significant survival benefits in patients with oligo-organ metastatic NSCLC who received first-line third-generation EGFR TKIs, with acceptable side effects. The administration of higher radiation doses during a phase of tumor shrinkage may be associated with optimal outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
聪明依柔完成签到 ,获得积分10
刚刚
1秒前
candiceli发布了新的文献求助20
1秒前
专注寻菱发布了新的文献求助10
1秒前
宋紫馨完成签到 ,获得积分10
2秒前
ali8ba完成签到,获得积分10
2秒前
三岁放火烧山完成签到,获得积分10
2秒前
dyy123完成签到,获得积分10
3秒前
Fayth完成签到,获得积分0
3秒前
江边拔草完成签到,获得积分10
3秒前
七安发布了新的文献求助10
3秒前
学术智子发布了新的文献求助10
4秒前
李健的小迷弟的应助被Sweetx采纳,获得10
5秒前
5秒前
awang发布了新的文献求助20
6秒前
Tong完成签到,获得积分10
6秒前
6秒前
如意听安完成签到,获得积分10
6秒前
领导范儿的应助被再睡亿分钟采纳,获得10
7秒前
7秒前
8秒前
mmol完成签到,获得积分10
8秒前
huang完成签到,获得积分10
9秒前
xixi发布了新的文献求助10
9秒前
七安完成签到,获得积分20
10秒前
赘婿的应助被dyy123采纳,获得10
10秒前
10秒前
10秒前
yy发布了新的文献求助10
10秒前
大模型的应助被zzh采纳,获得10
10秒前
John_Xiong完成签到,获得积分10
11秒前
华圣拿下巨蜥完成签到,获得积分10
11秒前
11秒前
11秒前
无花果的应助被远方采纳,获得10
11秒前
11秒前
ws发布了新的文献求助10
11秒前
12秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651